T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| 1 |
Roper Technologies
ROP
|
$795M |
| 2 |
Abbott
ABT
|
$750M |
| 3 |
Thermo Fisher Scientific
TMO
|
$746M |
| 4 |
Becton Dickinson
BDX
|
$730M |
| 5 |
Cigna
CI
|
$725M |
Top Sells
| 1 |
Salesforce
CRM
|
$1.32B |
| 2 |
Martin Marietta Materials
MLM
|
$959M |
| 3 |
Linde
LIN
|
$839M |
| 4 |
AbbVie
ABBV
|
$829M |
| 5 |
Intercontinental Exchange
ICE
|
$814M |
Sector Composition
| 1 | Technology | 26.31% |
| 2 | Healthcare | 20.82% |
| 3 | Consumer Discretionary | 12.47% |
| 4 | Industrials | 10.66% |
| 5 | Financials | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
576
Schlumberger
SLB
$53.4B
| $4.94M | ﹤0.01% |
128,821
+42,585
| +49% | +$1.63M |
|
577
Cencora
COR
$56.7B
| $4.91M | ﹤0.01% |
+21,871
| New | +$4.91M |
|
578
Applied Therapeutics
APLT
$68.2M
| $4.64M | ﹤0.01% |
5,420,920
+5,213,370
| +2,512% | +$4.46M |
|
579
Guidewire Software
GWRE
$22B
| $4.5M | ﹤0.01% |
+26,700
| New | +$4.5M |
|
|
BBOT
580
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$784M
| $4.2M | ﹤0.01% |
400,247
+2,598
| +0.7% | +$27.3K |
|
581
WEC Energy
WEC
$34.7B
| $4.09M | ﹤0.01% |
43,528
+8,009
| +23% | +$753K |
|
582
KLA
KLAC
$119B
| $3.59M | ﹤0.01% |
5,690
+1,975
| +53% | +$1.24M |
|
583
Informatica
INFA
$7.55B
| $3.58M | ﹤0.01% |
137,975
+45,455
| +49% | +$1.18M |
|
584
Floor & Decor
FND
$9.42B
| $3.4M | ﹤0.01% |
34,057
-391,952
| -92% | -$39.1M |
|
585
Xcel Energy
XEL
$43B
| $3.26M | ﹤0.01% |
48,201
+9,428
| +24% | +$637K |
|
586
Grocery Outlet
GO
$1.8B
| $3.04M | ﹤0.01% |
+194,551
| New | +$3.04M |
|
587
Toro Company
TTC
$8.06B
| $2.7M | ﹤0.01% |
33,695
-203,330
| -86% | -$16.3M |
|
588
RxSight
RXST
$364M
| $2.51M | ﹤0.01% |
73,027
-3,006
| -4% | -$103K |
|
589
AppFolio
APPF
$10.2B
| $2.14M | ﹤0.01% |
8,672
-77,452
| -90% | -$19.1M |
|
590
JPMorgan Chase
JPM
$809B
| $1.95M | ﹤0.01% |
8,139
-137
| -2% | -$32.8K |
|
591
Fabrinet
FN
$13.2B
| $1.95M | ﹤0.01% |
+8,844
| New | +$1.95M |
|
592
Jasper Therapeutics
JSPR
$44.2M
| $1.76M | ﹤0.01% |
+82,165
| New | +$1.76M |
|
593
Robert Half
RHI
$3.77B
| $1.67M | ﹤0.01% |
+23,664
| New | +$1.67M |
|
594
EyePoint Pharmaceuticals
EYPT
$966M
| $1.54M | ﹤0.01% |
206,939
-1,061,815
| -84% | -$7.91M |
|
595
Apellis Pharmaceuticals
APLS
$3.55B
| $1.52M | ﹤0.01% |
47,713
-2,937,559
| -98% | -$93.8M |
|
|
LB
596
LandBridge Company LLC
LB
$1.32B
| $1.43M | ﹤0.01% |
+22,137
| New | +$1.43M |
|
597
S&P Global
SPGI
$164B
| $1.29M | ﹤0.01% |
2,598
-6,685
| -72% | -$3.33M |
|
598
Procter & Gamble
PG
$375B
| $1.26M | ﹤0.01% |
7,494
+248
| +3% | +$41.6K |
|
599
Exxon Mobil
XOM
$466B
| $1.18M | ﹤0.01% |
10,985
| – | – |
|
600
Bank of America
BAC
$369B
| $1.08M | ﹤0.01% |
24,506
-3,533
| -13% | -$155K |
|